Pilot Study Evaluating the Acceptability and Absorption of the Bioactive Compounds of a Russian Tarragon Nutrasorb Bar

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-25

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to make a bar from the soy-protein Russian Tarragon complex (PMI-5011/Nutrasorb) that is safe and acceptable for consumption, and to test the blood levels of plasma bioactive (DMC-2) after ingestion of the bar. The PMI-5011/Nutrasorb comes from a plant source called Artemisia dracunculus. This plant has a long history of medicinal (health) and culinary (food) use and has been reported as effective as a traditional treatment for diabetes in various parts of the world.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)

NCT02088203

Diabetes Prevention

COMPLETED PHASE1

Effect of a Dietary Supplement on Quality of Life

NCT05323084

Quality of Life

COMPLETED NA

Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability

NCT00963118

Metabolic Syndrome

COMPLETED NA

Relative Bioavailability of Two Different Milk Thistle Formulations

NCT02529605

Healthy

COMPLETED NA

Tolerance Profile of Soluble Fibers in Individuals With Self-perceived GI Sensitivity to Fibers (Tarine)

NCT06877013

Population With Self-perceived Gastro-intestinal Sensitivity to Fibers

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase 1

Test Day: Fasting Visit (nothing to eat or drink other than water beginning at 10 pm the night before the test day); visit will be approximately 1 ½ hours.

The following procedures will be done on the Test Day:

* Informed consent will be signed by those agreeing to participate.
* Body weight and height will be measured (body mass index will be calculated from these measures).
* Participants will provide a list of any medications they are currently taking.
* Blood pressure and pulse will be measured.
* Taste test of the study bar will be conducted.
* Participants will answer questions regarding the appearance, smell, taste, texture, aftertaste, and pleasantness of the bar.

Phase 1 participants may be asked to return up to two additional times to complete the taste test and questions again. This will occur if the product is found unacceptable and will be completed after a new bar is produced.

Phase 2

Screening Visit: Fasting Visit (nothing to eat or drink other than water after 10 pm the night before the Screening Visit); visit will be approximately 1 ½ hours.

The following procedures will be done on the Screening Visit:

* Informed consent will be signed by those agreeing to participate.
* Body weight and height will be measured (body mass index will be calculated from these measures).
* Blood pressure and pulse will be measured.
* Medical history questionnaire will be completed.
* Blood will be drawn (approximately 2 teaspoons) to assess overall health.

Test Day: Fasting visit (nothing to eat or drink other than water after 10 pm the night before the Test Day); visit will be approximately 4 hours and will be completed within 30 days after Screening Visit.

The following procedures will be done on the Test Day:

* Blood will be drawn from an IV line placed in the participant's arm to assess the level of nutrients, blood sugar levels, and insulin levels from the study bar 10 minutes before the bar is consumed, immediately after the bar is consumed, and 30, 60, 120, and 180 minutes after the bar is consumed. A total of approximately 6 teaspoons of blood will be drawn for this Test Day.
* Participants will answer questions regarding the appearance, smell, taste, texture, aftertaste, and pleasantness of the bar.
* Participants will be asked about any side effects and how they feel throughout the Test Day.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nutrasorb bar evaluation

Participants in Phase 1 will taste test the bar for acceptability. Participants in Phase 2 will consume the bar and have blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2).

Nutrasorb bar

Intervention Type DIETARY_SUPPLEMENT

250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nutrasorb bar

250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males or females between 18 and 50 years of age inclusive.
* Body mass index between 20-30 kg/m2.

Exclusion Criteria

* Pregnant or currently lactating.
* Taking any prescription medications.
* Taking any over-the-counter medications that cannot be stopped for test days.
* Allergic to any ingredients contained in the bar.
* Other conditions or situations that would interfere with the study or the participant's safety as determined by the investigators.
* Participants in Phase 1 of the study may not participate in Phase 2 of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes